Human Papillomavirus, Vaccines and Women's Health
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Papillomavirus Vaccines".
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 10661
Special Issue Editor
Interests: ovarian cancer; biochemistry; genetics and molecular biology; medicine; pharmacology, toxicology and pharmaceutics; immunology and microbiology
Special Issue Information
Dear Colleagues,
In past decades, the results of a long research journey led to the introduction of HPV vaccination for the prevention of cervical dysplasia into routine clinical practice. This scientific achievement represents a cornerstone in medical history, since for the first time we have a reliable and effective primary prevention strategy able to reduce the incidence of a highly lethal malignancy: cervical cancer. Furthermore, HPV vaccination has progressively emerged as a potentially useful preventive strategy not only for uterine malignancies and vulvar condylomas, but also for anal carcinoma and head and neck cancer which may be sustained by HPV infection. As a further advancement, compelling evidences seem to suggest that HPV vaccination may be useful as a secondary preventive strategy in patients receiving surgery for cervical dysplasia, reducing the risk of recurrence. For these reasons, HPV vaccination is progressively emerging as a safe and useful tool to preserve overall women’s health.
On the other hand, several questions remain to be addressed by the scientific community. First of all, despite the relevant benefits for women’s health, the diffusion of HPV vaccination among young teenagers remain unsatisfying, particularly in low-income areas. Furthermore, from a biological point of view, the cross protection ensured by the available vaccines against the plethora of HPV serotypes remains to be clarified; moreover, little and contrasting data have been provided regarding the potential mechanisms of viral immunological escape. Finally, from a clinical point of view, the scientific community should start to look at HPV vaccination not only as a gynecological issue, but as a general health strategy involving several fields including oncological prevention for head & neck, lung, and proctological malignancies, thus focusing more efforts on the potential relevant overall benefits of HPV vaccination also in the male population.
Following this intriguing scenario, the main objective of this Special Issue is to provide novel interesting insights regarding HPV vaccination and its potential implications for women’s health of HPV vaccination to the scientific community, moving from primary and secondary prevention of cervical dysplasia and vulvar/anal condylomas to other non-gynecological issues including proctological diseases, head & neck and lung malignancies, as well as HPV-related couple fertility problems. Furthermore, we especially welcome original research papers and review articles providing high-quality rigorous novel insights regarding biological issues related to HPV vaccination (cross-protection, mechanisms of immunological escape, etc.), as well as epidemiological and community studies investigating the issues of HPV vaccination initiatives all over the world.
With the hope of an enthusiastic participation of the scientific community, we launch here the Vaccines Special Issue entitled: “Human Papillomavirus, Vaccines and Women's Health.”
Dr. Marco Petrillo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HPV vaccination
- condylomas
- cervical cancer
- head and neck cancer
- anal cancer
- lung cancer
- immunological escape
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
